This updated analysis of a subset in the ASSURE clinical trial examines the disease-free survival and overall survival of high-risk patients with clear cell renal cancer treated with sunitinib, sorafenib, or placebo.
http://ift.tt/2mL6oih
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
-
Summary Insulinomas are rare neuroendocrine tumours that classically present with fasting hypoglycaemia. This case report discusses an un...
-
The online platform for Taylor & Francis Online content New for Canadian Journal of Remote Sen...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου